FRM
DNLI icon

Fox Run Management’s Denali Therapeutics DNLI Stock Holding History

Fox Run Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-38,668
Closed -$788K – 975
2024
Q4 		$788K Buy
+38,668
New +$990K 0.14% 252
2024
Q3 		– Sell
-24,390
Closed -$566K – 866
2024
Q2 		$566K Buy
+24,390
New +$468K 0.11% 361
2023
Q3 		– Sell
-12,478
Closed -$368K – 766
2023
Q2 		$368K Buy
12,478
+3,561
+40% +$100K 0.1% 375
2023
Q1 		$205K Buy
+8,917
New +$245K 0.07% 528
2022
Q4 		– Sell
-14,977
Closed -$460K – 684
2022
Q3 		$460K Buy
+14,977
New +$487K 0.18% 199

Other funds holding DNLI

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $29.7B AUM 13.98% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return